Trade ReShape Lifesciences Inc. - RSLS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | 0.42 |
1-Year Change* | 10.53% |
Day's Range* | 0.38 - 0.55 |
52 wk Range | 0.15-2.22 |
Average Volume (10 days) | 204.12K |
Average Volume (3 months) | 3.86M |
Market Cap | 4.21M |
P/E Ratio | -100.00K |
Shares Outstanding | 24.18M |
Revenue | 12.18M |
EPS | -4.40 |
Dividend (Yield %) | N/A |
Beta | -0.18 |
Next Earnings Date | Mar 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 13, 2023 | 0.38 | -0.02 | -5.00% | 0.40 | 0.55 | 0.38 |
Oct 12, 2023 | 0.40 | -0.01 | -2.44% | 0.41 | 0.49 | 0.38 |
Sep 29, 2023 | 0.40 | -0.05 | -11.11% | 0.45 | 0.49 | 0.38 |
Sep 28, 2023 | 0.41 | -0.11 | -21.15% | 0.52 | 0.55 | 0.41 |
Sep 27, 2023 | 0.50 | -0.01 | -1.96% | 0.51 | 0.51 | 0.50 |
Sep 26, 2023 | 0.57 | -0.01 | -1.72% | 0.58 | 0.60 | 0.57 |
Sep 25, 2023 | 0.59 | 0.02 | 3.51% | 0.57 | 0.59 | 0.55 |
Sep 22, 2023 | 0.57 | -0.04 | -6.56% | 0.61 | 0.62 | 0.57 |
Sep 21, 2023 | 0.58 | -0.06 | -9.38% | 0.64 | 0.64 | 0.57 |
Sep 20, 2023 | 0.64 | 0.03 | 4.92% | 0.61 | 0.65 | 0.61 |
Sep 19, 2023 | 0.63 | -0.05 | -7.35% | 0.68 | 0.68 | 0.62 |
Sep 18, 2023 | 0.67 | -0.06 | -8.22% | 0.73 | 0.73 | 0.65 |
Sep 15, 2023 | 0.70 | 0.00 | 0.00% | 0.70 | 0.70 | 0.68 |
Sep 14, 2023 | 0.74 | -0.05 | -6.33% | 0.79 | 0.79 | 0.72 |
Sep 13, 2023 | 0.73 | 0.00 | 0.00% | 0.73 | 0.75 | 0.73 |
Sep 12, 2023 | 0.78 | -0.07 | -8.24% | 0.85 | 0.85 | 0.76 |
Sep 11, 2023 | 0.85 | -0.02 | -2.30% | 0.87 | 0.87 | 0.82 |
Sep 8, 2023 | 0.81 | -0.05 | -5.81% | 0.86 | 0.86 | 0.79 |
Sep 7, 2023 | 0.84 | -0.05 | -5.62% | 0.89 | 0.90 | 0.84 |
Sep 6, 2023 | 0.91 | 0.03 | 3.41% | 0.88 | 1.25 | 0.88 |
ReShape Lifesciences Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 13.6 | 1.588 | 3.281 | 9.101 | 9.914 |
Revenue | 13.6 | 1.588 | 3.281 | 9.101 | 9.914 |
Cost of Revenue, Total | 5.252 | 1.004 | 2.95 | 5.423 | 4.829 |
Gross Profit | 8.348 | 0.584 | 0.331 | 3.678 | 5.085 |
Total Operating Expense | 72.162 | 13.54 | 26.511 | 46.066 | 44.305 |
Selling/General/Admin. Expenses, Total | 31.275 | 8.776 | 16.668 | 29.946 | 28.829 |
Research & Development | 2.522 | 2.45 | 6.893 | 10.697 | 10.647 |
Operating Income | -58.562 | -11.952 | -23.23 | -36.965 | -34.391 |
Interest Income (Expense), Net Non-Operating | -0.664 | 0.029 | -0.385 | -0.226 | -0.135 |
Other, Net | -2.813 | -0.411 | -0.061 | -0.189 | -0.239 |
Net Income Before Taxes | -62.039 | -12.334 | -23.676 | -37.38 | -34.765 |
Net Income After Taxes | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Net Income Before Extra. Items | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Net Income | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Income Available to Common Excl. Extra. Items | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Income Available to Common Incl. Extra. Items | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Diluted Net Income | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Diluted Weighted Average Shares | 12.3785 | 2.57943 | 1.56891 | 0.63455 | 0.55723 |
Diluted EPS Excluding Extraordinary Items | -5.00327 | -4.78168 | -15.0907 | -58.9079 | -62.3888 |
Diluted Normalized EPS | -3.26449 | -4.27382 | -15.0907 | -58.9079 | -62.3888 |
Total Extraordinary Items | 0 | ||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Unusual Expense (Income) | 33.113 | 1.31 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 2.44 | 3.142 | 3.708 | 3.529 | 3.221 |
Revenue | 2.44 | 3.142 | 3.708 | 3.529 | 3.221 |
Cost of Revenue, Total | 1.222 | 1.366 | 1.573 | 1.376 | 0.937 |
Gross Profit | 1.218 | 1.776 | 2.135 | 2.153 | 2.284 |
Total Operating Expense | 10.84 | 38.699 | 18.692 | 7.332 | 7.438 |
Selling/General/Admin. Expenses, Total | 8.87 | 8.304 | 15.548 | 5.752 | 3.97 |
Research & Development | 0.748 | 0.277 | 1.571 | 0.103 | 0.571 |
Unusual Expense (Income) | 0 | 28.752 | 0 | 0.101 | 1.96 |
Operating Income | -8.4 | -35.557 | -14.984 | -3.803 | -4.217 |
Interest Income (Expense), Net Non-Operating | 0.015 | -0.03 | 0.068 | -0.071 | -0.632 |
Other, Net | 0.013 | 0 | -2.813 | 0 | |
Net Income Before Taxes | -8.372 | -35.587 | -17.729 | -3.874 | -4.849 |
Net Income After Taxes | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Net Income Before Extra. Items | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Net Income | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Income Available to Common Excl. Extra. Items | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Income Available to Common Incl. Extra. Items | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Diluted Net Income | -8.215 | -35.458 | -17.699 | -3.902 | -4.874 |
Diluted Weighted Average Shares | 18.5396 | 17.874 | 11.9974 | 8.22614 | 3.92799 |
Diluted EPS Excluding Extraordinary Items | -0.44311 | -1.98378 | -1.47524 | -0.47434 | -1.24084 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.44311 | -0.93819 | -1.47524 | -0.46636 | -0.9165 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 30.255 | 7.835 | 18.235 | 28.647 | 51.755 |
Cash and Short Term Investments | 22.765 | 3.905 | 14.055 | 23.735 | 44.4 |
Cash & Equivalents | 22.765 | 3.905 | 14.055 | 21.187 | 21.108 |
Short Term Investments | 0 | 2.548 | 23.292 | ||
Total Receivables, Net | 2.815 | 3.15 | 0.285 | 0.882 | 4.308 |
Accounts Receivable - Trade, Net | 2.815 | 0 | 0.285 | 0.87 | 4.223 |
Total Inventory | 3.003 | 0 | 1.936 | 1.58 | 1.418 |
Prepaid Expenses | 0.736 | 0.599 | 1.89 | 2.329 | 1.514 |
Other Current Assets, Total | 0.936 | 0.181 | 0.069 | 0.121 | 0.115 |
Total Assets | 54.258 | 10.617 | 20.393 | 30.386 | 53.101 |
Property/Plant/Equipment, Total - Net | 1.72 | 1.478 | 2.158 | 1.739 | 1.346 |
Property/Plant/Equipment, Total - Gross | 2.06 | 4.082 | 4.484 | 3.718 | 2.761 |
Accumulated Depreciation, Total | -0.34 | -2.604 | -2.326 | -1.979 | -1.415 |
Total Current Liabilities | 7.331 | 5.046 | 3.977 | 17.231 | 10.011 |
Payable/Accrued | 3.468 | ||||
Accrued Expenses | 2.407 | 4.431 | 2.881 | 5.79 | 6.267 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.024 | 9.93 | 1.958 | |
Other Current Liabilities, Total | 1.456 | 0 | 0.424 | 0.352 | 0.51 |
Total Liabilities | 8.186 | 5.952 | 4.544 | 17.279 | 17.988 |
Total Long Term Debt | 0 | 0.43 | 0 | 0 | 7.964 |
Long Term Debt | 0 | 0.43 | 0 | 7.964 | |
Total Equity | 46.072 | 4.665 | 15.849 | 13.107 | 35.113 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 0.018 | 0.008 | 0.008 | 0.023 | 0.018 |
Additional Paid-In Capital | 622.906 | 189.421 | 188.271 | 161.838 | 146.474 |
Retained Earnings (Accumulated Deficit) | -576.76 | -184.764 | -172.43 | -148.754 | -111.374 |
Other Equity, Total | -0.092 | 0 | -0.005 | ||
Total Liabilities & Shareholders’ Equity | 54.258 | 10.617 | 20.393 | 30.386 | 53.101 |
Total Common Shares Outstanding | 17.8319 | 2.59021 | 2.57467 | 0.78377 | 0.58335 |
Accounts Payable | 0.615 | 0.648 | 1.159 | 1.276 | |
Other Liabilities, Total | 0.3 | 0.476 | 0.567 | 0.048 | 0.013 |
Other Long Term Assets, Total | 1.456 | 1.304 | |||
Intangibles, Net | 20.827 | ||||
Deferred Income Tax | 0.555 | ||||
Total Preferred Shares Outstanding | 0.09539 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 23.627 | 30.255 | 37.589 | 65.605 | 12.794 |
Cash and Short Term Investments | 15.41 | 22.765 | 29.243 | 40.163 | 8.972 |
Cash & Equivalents | 15.41 | 22.765 | 29.243 | 40.163 | 8.972 |
Total Receivables, Net | 2.41 | 2.815 | 3.457 | 3.422 | 3.15 |
Prepaid Expenses | 0.597 | 0.736 | 0.693 | 1.114 | 0.495 |
Other Current Assets, Total | 1.212 | 0.936 | 0.99 | 18.012 | 0.177 |
Total Assets | 47.27 | 54.258 | 90.698 | 120 | 17.343 |
Property/Plant/Equipment, Total - Net | 1.895 | 1.72 | 2.052 | 2.22 | 1.312 |
Property/Plant/Equipment, Total - Gross | 0.524 | 2.06 | 0.45 | 0.632 | 3.982 |
Accumulated Depreciation, Total | -0.34 | -2.67 | |||
Other Long Term Assets, Total | 1.377 | 1.456 | 1.535 | 1.628 | 3.237 |
Total Current Liabilities | 8.151 | 7.331 | 10.336 | 60.496 | 6.863 |
Accounts Payable | 3.095 | 0.582 | |||
Accrued Expenses | 2.695 | 2.899 | 3.128 | 53.479 | 5.851 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 2.971 | 2.936 | 0.43 | |
Total Liabilities | 8.645 | 8.186 | 11.478 | 61.881 | 7.245 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | 0 | 0 | 0 | |
Other Liabilities, Total | 0.127 | 0.3 | 0.527 | 0.77 | 0.382 |
Total Equity | 38.625 | 46.072 | 79.22 | 58.119 | 10.098 |
Common Stock | 0.019 | 0.018 | 0.018 | 0.008 | 0.01 |
Additional Paid-In Capital | 623.652 | 622.906 | 620.611 | 581.823 | 199.019 |
Retained Earnings (Accumulated Deficit) | -584.975 | -576.76 | -541.302 | -523.603 | -188.931 |
Total Liabilities & Shareholders’ Equity | 47.27 | 54.258 | 90.698 | 120 | 17.343 |
Total Common Shares Outstanding | 18.5975 | 17.8319 | 17.6883 | 8.16862 | 3.34052 |
Accounts Receivable - Trade, Net | 2.41 | 2.815 | 3.457 | 3.422 | |
Total Inventory | 3.998 | 3.003 | 3.206 | 2.894 | |
Goodwill, Net | 21.053 | 21.623 | |||
Intangibles, Net | 20.371 | 20.827 | 28.469 | 28.924 | |
Other Current Liabilities, Total | 1.858 | 0.964 | 1.125 | 0.986 | |
Deferred Income Tax | 0.367 | 0.555 | 0.615 | 0.615 | |
Other Equity, Total | -0.071 | -0.092 | -0.107 | -0.109 | |
Payable/Accrued | 3.598 | 3.468 | 3.112 | ||
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Total Preferred Shares Outstanding | 0.09539 | 0.09539 | 0.09539 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -61.933 | -12.334 | -23.676 | -37.38 | -34.765 |
Cash From Operating Activities | -15.375 | -10.409 | -22.866 | -29.432 | -30.624 |
Cash From Operating Activities | 0.232 | 0.34 | 0.479 | 0.581 | 0.33 |
Non-Cash Items | 47.388 | 2.985 | 3.594 | 4.787 | 4.907 |
Cash Taxes Paid | 0.102 | 0 | 0 | 0.007 | 0.002 |
Cash Interest Paid | 0.296 | 0 | 0.719 | 0.642 | 0.562 |
Changes in Working Capital | -2.741 | -1.4 | -3.263 | 2.58 | -1.096 |
Cash From Investing Activities | 1.855 | -0.171 | 2.356 | 19.517 | -21.856 |
Capital Expenditures | -0.352 | -0.171 | -0.194 | -1.282 | -1.043 |
Other Investing Cash Flow Items, Total | 2.207 | 0 | 2.55 | 20.799 | -20.813 |
Cash From Financing Activities | 33.299 | 0.43 | 13.378 | 9.994 | 0.613 |
Financing Cash Flow Items | -3.234 | 0 | -0.03 | 0 | |
Issuance (Retirement) of Stock, Net | 46.033 | 0 | 23.378 | 10.024 | 0.613 |
Issuance (Retirement) of Debt, Net | -9.5 | 0.43 | -10 | 0 | |
Foreign Exchange Effects | 0.029 | 0 | |||
Net Change in Cash | 19.808 | -10.15 | -7.132 | 0.079 | -51.867 |
Amortization | 1.739 | ||||
Deferred Taxes | -0.06 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.215 | -61.933 | -26.475 | -8.776 | -4.874 |
Cash From Operating Activities | -7.378 | -15.375 | -11.949 | -4.149 | -1.961 |
Cash From Operating Activities | 0.094 | 0.232 | 0.132 | 0.04 | 0.007 |
Amortization | 0.456 | 1.739 | 1.284 | 0.828 | 0.411 |
Deferred Taxes | -0.187 | -0.06 | 0 | ||
Non-Cash Items | 0.831 | 47.388 | 16.165 | 2.454 | 2.61 |
Cash Taxes Paid | 0 | 0.102 | 0.037 | 0.031 | 0.031 |
Changes in Working Capital | -0.357 | -2.741 | -3.055 | 1.305 | -0.115 |
Cash From Investing Activities | 0.002 | 1.855 | 4.922 | 5.011 | -0.119 |
Capital Expenditures | -0.007 | -0.352 | -0.285 | -0.196 | -0.119 |
Other Investing Cash Flow Items, Total | 0.009 | 2.207 | 5.207 | 5.207 | 0 |
Cash From Financing Activities | 0 | 33.299 | 33.299 | 36.332 | 1 |
Issuance (Retirement) of Debt, Net | 0 | -9.5 | -9.5 | -9.5 | 1 |
Foreign Exchange Effects | 0.021 | 0.029 | 0.014 | 0.012 | 0.019 |
Net Change in Cash | -7.355 | 19.808 | 26.286 | 37.206 | -1.061 |
Cash Interest Paid | 0.296 | 0.296 | 0.296 | ||
Issuance (Retirement) of Stock, Net | 46.033 | 46.033 | 45.832 | ||
Financing Cash Flow Items | -3.234 | -3.234 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ReShape Lifesciences Inc. Company profile
About ReShape Lifesciences Inc
ReShape Lifesciences Inc., formerly Obalon Therapeutics, Inc., is a weight-loss solutions company. The Company is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The Company's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ReShape Lifesciences Inc revenues increased from $1.5M to $10.5M. Net loss increased from $11M to $26.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $790K to $8.1M (expense), Selling, general and administrative - B increase of 62% to $10.9M (expense).
Industry: | Advanced Medical Equipment & Technology (NEC) |
1001 Calle Amanecer
SAN CLEMENTE
CALIFORNIA 92673
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com